Sort
10,766 grants matching “checkpoint inhibitor”
FASEB's The Autoimmunity Conference
$10,000Dario Aa Vignali · Federation Of Amer Soc For Exper Biology · R13 · FY2021 · AI
The Midwest Tumor Microenvironment Meeting
$10,000Lisa M Arendt · University Of Wisconsin-Madison · R13 · FY2024 · CA
Gastrointestinal Cancer Research Program (GI) (Project-005)
$10,000Jordan D Berlin · Vanderbilt University Medical Center · P30 · FY2018 · CA
Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity
$10,000Thale Cross Jarvis · Keystone Symposia · R13 · FY2019 · CA
Translational & Clinical Research (TACR) Program
$9,970Muneesh Tewari · University Of Michigan At Ann Arbor · P30 · FY2018 · CA
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
$9,932Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Clinical Investigation and Precision Therapy
$9,429Shridar Ganesan · Rutgers Biomedical And Health Sciences · P30 · FY2024 · CA
Cancer Pharmacology
$9,429Xiaofeng Steven Zheng · Rutgers Biomedical And Health Sciences · P30 · FY2024 · CA
Genomic Instability and Cancer Genetics
$9,429Chang S Chan · Rutgers Biomedical And Health Sciences · P30 · FY2024 · CA
Improving Efficacy and Safety of VSV Immunotherapy for Metastatic Melanoma
$9,418Kevin G Shim · Mayo Clinic Rochester · F30 · FY2019 · CA
Project 1: Targeted sequencing and clinicopathology to evaluate primary melanoma molecular subtypes and outcomes
$9,299Marianne Berwick · University Of New Mexico Health Scis Ctr · P01 · FY2019 · CA
GU Malignancies Research Program
$9,258Brian I Rini · Case Western Reserve University · P30 · FY2018 · CA
Developmental Therapeutics Research Program
$9,258John James Letterio · Case Western Reserve University · P30 · FY2018 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
$9,250Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Translational & Clinical Research (TACR) Program
$8,971Muneesh Tewari · University Of Michigan At Ann Arbor · P30 · FY2018 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$8,612Robert M Prins · University Of California Los Angeles · P50 · FY2025 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$8,561Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2020 · CA
Examining the impact of laboratory housing temperature on murine CD28 and the response to anti-PD-1
$8,385Caitlin M James · Roswell Park Cancer Institute Corp · F31 · FY2025 · CA
Immunology
$8,049Claudio Anasetti · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2018 · CA
Cancer Immunotherapy: Combinations
$8,000Thale Cross Jarvis · Keystone Symposia · R13 · FY2018 · CA
Gastrointestinal Cancer Research Program (GI) (Project-005)
$7,997Jordan D Berlin · Vanderbilt University Medical Center · P30 · FY2018 · CA
Gastrointestinal Cancer Research Program (GI) (Project-005)
$7,968Jordan D Berlin · Vanderbilt University Medical Center · P30 · FY2018 · CA
Lymphoma & Leukemia Research Program (Project-007)
$7,796Ronald Levy · Stanford University · P30 · FY2018 · CA
Translational & Clinical Research (TACR) Program
$7,661Muneesh Tewari · University Of Michigan At Ann Arbor · P30 · FY2018 · CA
B7x in Cancer: Mechanisms and Therapies
$7,529Peter John · Albert Einstein College Of Medicine · F30 · FY2018 · CA